Stealth Peptides Inc. Release: Leading Cardiovascular Researchers Present Promising Bendavia Findings at 2013 European Society of Cardiology Heart Failure Congress

Published: Jun 24, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ findings presented by leading cardiovascular researchers at the European Society of Cardiology (ESC) Heart Failure Congress. Several researchers from Europe and the United States, including Drs. Hani Sabbah and Hazel Szeto, reported on seven recent studies demonstrating Bendavia’s ability to improve cardiac function, preserve viable myocardium and increase survival in systolic and diastolic heart failure models. Stealth is a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs including heart failure and chronic kidney disease. Bendavia is a novel compound that targets mitochondria, restoring bioenergetics in the failing heart. ESC represents more than 80,000 cardiology professionals and provides an array of scientific and educational services and activities. The 2013 Heart Failure Congress was held in Lisbon, Portugal, and is the world’s largest international heart failure congress.

Help employers find you! Check out all the jobs and post your resume.

Back to news